Sign in

    Brandon Carney

    Senior Research Associate at B. Riley

    Brandon Carney is a Senior Research Associate at B. Riley Securities, specializing in healthcare equity research with a focus on oncology, radiopharma, and biotechnology sectors. He actively covers a range of small and mid-cap public and private companies in the oncology and precision medicine space, participating in industry conferences such as the B. Riley Precision Oncology and Radiopharma Conference. Carney joined B. Riley Securities in 2024 after holding previous roles in corporate finance at Hanger Clinic and postdoctoral research at Stony Brook University. He brings a strong scientific background to his analyst role, with experience in academic research and investment analysis, though specific performance metrics or professional securities licenses are not publicly available.

    Brandon Carney's questions to Hyperfine (HYPR) leadership

    Brandon Carney's questions to Hyperfine (HYPR) leadership • Q2 2025

    Question

    Brandon Carney of B. Riley Securities questioned the factors behind the Q2 ASP increase, whether the upcoming international hardware launch could delay customer orders, and if the SWOOP system has a special use case for patients with neuro implants.

    Answer

    CFO Brett Hale attributed the Q2 ASP increase to a favorable sales channel mix, MSRP increases from earlier in the year, and the first sale of the higher-priced next-generation system. CEO Maria Sainz stated that internationally, the new OptiV AI software will be available by year-end, providing a significant image quality upgrade that should sustain demand before the new hardware arrives in 2026. Regarding implants, Sainz confirmed the low-field magnet offers a significant safety advantage, reducing interference from devices like pacemakers and even dental braces, and highlighted a more favorable FDA label regarding projectile risk.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to Hyperfine (HYPR) leadership • Q4 2024

    Question

    Asked for more color on the NVIDIA partnership, inquired about the progress and customer feedback regarding the expansion into neurology offices, and questioned how the customer mix is expected to evolve with the expansion outside of critical care.

    Answer

    The company reiterated that they would not provide additional commentary on the NVIDIA partnership. Regarding the neurology office expansion, they have been in a successful pilot mode, finding the accreditation and implementation processes to be seamless. They are also conducting the Neuro PMR study to validate use cases and have seen strong interest from neurologists. The customer mix in the second half of 2025 is expected to be more diversified across neurology offices (U.S. only), multiple hospital sites, and international markets, which should lead to more predictable revenue.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to Hyperfine (HYPR) leadership • Q4 2024

    Question

    Brandon Carney of B. Riley followed up on the NVIDIA partnership, asking about the mutual benefits and any specific deliverables. He also questioned the expansion into neurology offices, seeking details on early progress and customer feedback, and asked for a general outlook on the customer mix as the company expands beyond critical care.

    Answer

    Executive Maria Sainz reiterated that no further details on the NVIDIA partnership would be shared, but noted a new technology release has been filed with the FDA. Regarding the neurology office expansion, she described a successful pilot program with a seamless accreditation process and highlighted the Neuro PMR study with the Dent Institute and Texas Neurology to validate use cases. She also mentioned strong interest from industry groups. On customer mix, Sainz explained the office expansion is U.S.-only while hospital growth is global, with timing dependent on factors like regulatory approval in India. CFO Brett Hale added that H2 2025 will feature a more diversified and balanced revenue portfolio.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to Varex Imaging (VREX) leadership

    Brandon Carney's questions to Varex Imaging (VREX) leadership • Q3 2025

    Question

    Brandon Carney of B. Riley Securities asked for an update on tariff mitigation strategies, whether the new India facility would immediately reduce tariff exposure, and if there were any supply chain risks related to US-India trade relations.

    Answer

    CFO Shubham Maheshwari described the company's tariff mitigation efforts as being in the 'mid-innings,' involving strategies like bonded warehouses, local manufacturing, and price pass-throughs. He clarified that the India plant's primary goal is cost-effective production for the global value-tier market, not solely tariff avoidance. He and CEO Sunny Sanyal also noted that there is no significant U.S. production dependency on components from India, minimizing potential trade-related risks.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to Varex Imaging (VREX) leadership • Q2 2025

    Question

    Brandon Carney from B. Riley Securities questioned if near-term tariff relief would have an immediate positive impact on the China outlook. He also asked about the expected recovery cadence for China sales from the low Q3 guidance and for an updated timeline on when the cargo inspection business might become margin accretive.

    Answer

    CFO Sam Maheshwari stated that near-term tariff relief could have an immediate impact on sales, as production has not stopped. CEO Sunny Sanyal added that a recovery in China sales could begin in Q4, contingent on the successful implementation of mitigation strategies by the end of Q3. Regarding the inspection business, Mr. Maheshwari clarified that it is at least two years away from being margin accretive, as this depends on generating a post-warranty service revenue stream.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to RadNet (RDNT) leadership

    Brandon Carney's questions to RadNet (RDNT) leadership • Q1 2025

    Question

    Brandon Carney of B. Riley Securities inquired about recent trends in capitation contracts, the pricing impact of radiopharmaceutical agents on the PET business, and the specific contribution of newer scans to PET/CT's growth.

    Answer

    CEO Howard Berger and CFO Mark Stolper explained that capitation is a decreasing percentage of revenue as they shift contracts to higher-rate fee-for-service models or secure significant rate increases. Mr. Stolper clarified that newer PET tracers are reimbursed on a pass-through basis with minimal margin impact. He specified that new prostate and Alzheimer's scans now constitute about 19% of the PET/CT business and are the primary drivers of its greater than 20% growth.

    Ask Fintool Equity Research AI

    Brandon Carney's questions to Perspective Therapeutics (CATX) leadership

    Brandon Carney's questions to Perspective Therapeutics (CATX) leadership • Q1 2023

    Question

    Brandon Carney from B. Riley inquired about the expected synergies from the Viewpoint merger, the perceived competition between brachytherapy and radiopharmaceutical therapies, and the ongoing role of gamma radiation from brachytherapy in light of the advantages of alpha particle therapy.

    Answer

    Thijs Spoor, CEO of Viewpoint Molecular Targeting, addressed the questions by outlining synergies in personnel, regulatory functions, and physician relationships. He clarified that brachytherapy and targeted alpha therapies are complementary, not competitive, often used in combination or for different cancer types and stages. Spoor explained that while alpha particles are highly effective for specific targeted tumors, gamma radiation from brachytherapy remains a vital, personalized treatment for other tumor types, like slow-growing prostate cancer, emphasizing a data-driven, evidence-based approach for each.

    Ask Fintool Equity Research AI